Neurogene Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In Thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows used in operating activities: | ||
| Net loss | $(36,317) | $(55,189) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,418 | 1,252 |
| Bargain purchase gain in connection with reverse merger | (16,355) | — |
| Depreciation and amortization of property and equipment | 3,262 | 3,196 |
| Non-cash operating lease expense | 663 | 608 |
| Amortization of finance lease right-of-use assets | 35 | 4 |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | (105) | — |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | 326 | 716 |
| Other assets | (764) | — |
| Accounts payable | 667 | (3,607) |
| Accrued expenses and other current liabilities | (3,574) | 806 |
| Operating lease liabilities | (678) | (610) |
| Net cash used in operating activities | (51,422) | (52,824) |
| Cash flows used in investing activities: | ||
| Purchases of property and equipment | (321) | (2,230) |
| Cash and restricted cash acquired from reverse merger transaction | 22,243 | — |
| Reverse merger transaction costs paid | (1,285) | — |
| Proceeds from maturities of held-to-maturity investments | 5,000 | — |
| Net cash used in investing activities | 25,637 | (2,230) |
| Cash flows provided by financing activities: | ||
| Proceeds from pre-closing financing, net of offering costs paid | 92,343 | — |
| Proceeds from issuance of Series B convertible preferred stock, net of offering costs paid | — | 66,459 |
| Proceeds from the issuance of common stock upon exercise of options | 168 | 73 |
| Principal payments on finance leases | (29) | (1) |
| Net cash provided by financing activities | 92,482 | 66,531 |
| Net increase in cash, cash equivalents and restricted cash | 66,697 | 11,477 |
| Cash, cash equivalents and restricted cash at beginning of year | 82,021 | 70,544 |
| Cash, cash equivalents and restricted cash at end of year | $148,718 | $82,021 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Additions to finance lease right of use assets from new finance lease liabilities | $46 | $91 |
| Operating lease liabilities assumed in connection with the reverse merger | $10,940 | $— |
| Contingent consideration liability assumed in the reverse merger | $1,287 | $— |
| Other liabilities assumed in the reverse merger | $10,110 | $— |
| Assets acquired in the reverse merger including $53.9 million in short-term investments and $0.8 million in other monetary assets | $54,661 | $— |
| Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger | $38,212 | $— |
| Offering costs in connection with pre-closing financing included in accounts payable and accrued expenses | $4,287 | $— |
| Transaction costs related to reverse merger included in accounts payable and accrued expenses | $2,855 | $— |
| Conversion of preferred stock into common stock in connection with reverse merger | $244,366 | $— |
| Supplemental cash flow information: | ||
| Cash paid for interest | $12 | $2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.